Int J Antimicrob Agents. 2013;41:337–42.PubMedCrossRef 43. Zhang H, Xiao M, Yang QW, et al. High ceftaroline non-susceptibility in Staphylococcus aureus isolated from acute skin infections in 15 tertiary hospitals in China. J Med Microbiol. 2012;62:496–7.PubMedCrossRef 44. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, AZD1480 manufacturer doubled-blinded, multicenter
phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51:1395–405.PubMedCrossRef 45. File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55:S173–80.PubMedCrossRef 46. Mandell LA, Wunderink RG, Anzueto A, et al.
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef 47. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure Nutlin-3a supplier infection. Clin Infect Dis. 2010;51:641–50.PubMedCrossRef 48. Forest Research Institute I. Briefing book—ceftaroline fosamil for injection; 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm224657.pdf (Accessed 9 July 2013). 49. Friedland HD, O’Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment
of acute bacterial skin and skin structure infections. Antimicrob Agents PCI-32765 Chemother. 2012;56:2231–6.PubMedCentralPubMedCrossRef 50. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with AMP deaminase community-acquired pneumonia. J Antimicrob Chemother. 2011;66:iii53–9. 51. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65:iv67–71. 52. Panagiotidis G, Backstrom T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54:1811–4.PubMedCentralPubMedCrossRef 53. Riccobene TA, Rekeda L, Rank D, Llorens L. Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Antimicrob Agents Chemother. 2013;57:1777–83.PubMedCentralPubMedCrossRef 54.